Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003853 · ClinicalTrials.gov registry record · Phase 2
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT00003853 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00003853, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients who have primary systemic amyloidosis.
Conditions Studied
Interventions
- DRUG 4'-iodo-4'-deoxydoxorubicin
Study Locations (3)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Minnesota
- Mayo Clinic Cancer Center - Rochester
Other
- University of Pavia - Pavia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-04 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003853
The ClinicalTrials.gov registry entry for NCT00003853 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (94% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which 4'-iodo-4'-deoxydoxorubicin is the first listed.
NCT00003853 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arkansas, Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT00003853 about?
NCT00003853 is a clinical study titled "4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis". RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients who have primary systemic amyloidosis.
What is the current status of trial NCT00003853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1999-04. Estimated completion is 2001-08.
What conditions does trial NCT00003853 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00003853?
The interventions under investigation include: 4'-iodo-4'-deoxydoxorubicin (DRUG).
Who is sponsoring clinical trial NCT00003853?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003853 being conducted?
This trial has 3 study locations across Arkansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
COMPLETED · Phase 2
-
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.